Search
Benzoylecgonine
go.drugbank.com/drugs/DB01515ExperimentalIllicitIt is the main pharmaceutical ingredient in the investigational drug Esterom, a topical solution used for the relief of muscle pain that is not FDA approved or on the market in the United States. … It is formed by hydrolysis of cocaine in the liver, catalysed by carboxylesterases. It is excreted in the urine of cocaine users after processing in the liver.
MDX-214
go.drugbank.com/drugs/DB06110ExperimentalIt is developed for the treatment of EGF-R overexpressing cancers. … MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector
Osemozotan
go.drugbank.com/drugs/DB05339ExperimentalMN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)
DCFBC F-18
go.drugbank.com/drugs/DB14772InvestigationalDCFBC F-18 is under investigation in clinical trial NCT02190279 (18F-DCFBC PET/CT in Prostate Cancer).
BD-111
go.drugbank.com/drugs/DB18247InvestigationalBD-111 is an HSV-1-erasing lentivirus-like particle delivering gRNA-expressing cassette and SpCas9 mRNA.
DT-DEC01
go.drugbank.com/drugs/DB19433ExperimentalDT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.
HSV-2 theracine
go.drugbank.com/drugs/DB05811ExperimentalHSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.
Asoprisnil
go.drugbank.com/drugs/DB06680InvestigationalAsoprisnil (J867) is a selective progesterone receptor modulator. It can be used to treat progesterone sensitive myomata.
ADC4022
go.drugbank.com/drugs/DB05195InvestigationalADC4022 is an investigational medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and severe asthma.
Chlorfenson
go.drugbank.com/drugs/DB05377ExperimentalChlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.